No abstract available.
Herpesvirus 3, Human* ; Korea*

No abstract available.
Chickenpox ; Herpesvirus 3, Human*

No abstract available.
DNA* ; Herpesvirus 3, Human*

No abstract available.
Herpesvirus 3, Human* ; Korea*

No abstract available.
Folliculitis* ; Herpesvirus 3, Human ; Scalp*

No abstract available.
Antibodies, Monoclonal* ; Herpesvirus 3, Human*

No abstract available.
Folliculitis ; Herpes Zoster ; Herpesvirus 3, Human

No abstract available.
Acyclovir ; Chickenpox* ; Child* ; Herpesvirus 3, Human* ; Humans

Varicella zoster virus (VZV) is a widespread human herpesvirus which causes chickenpox (varicella). VZV infection can produce a broad spectrum of neurologic disorders including multiple cranial nerve palsies. Among the cranial nerves, trigeminal and facial nerves are the most commonly involved. However, multiple lower cranial nerve palsies caused by VZV infection is very rare. It is a diagnostic dilemma for VZV infection if there are no skin or mucosa lesions, which are characteristic signs of VZV infection. We report the case of a 54-year-old man with sudden right hearing loss, sore throat, odynophagia, hoarseness, dysphagia and vertigo. Pure tone audiometry revealed right sensorineural hearing loss and laryngoscopy proved that there were paralyses of the right upper pharyngeal constrictor muscle and vocal cord. These findings were consistent with acute unilateral vestibulocochlear, glossopharyngeal and vagus nerve palsies. There were no skin or mucosa lesions noted in our patient. The diagnosis was assisted by the existence of anti-VZV serum IgM even if the polymerase chain reaction result was negative. The symptoms of the patient improved after receiving anti-viral therapy. We emphasize the role of VZV infection in multiple cranial nerve palsies and the importance of serologic test.
Herpesvirus 3, Human ; Cranial Nerve Diseases

Standard plaque assay using agarose-overlay has long been used for titration of many infectious virus particle. Plaque assay for the titration of varicella-zoster virus and its live vaccine requires three intermittent agarose overlay to visualize plaques. Overall procedure of the assay takes at least nine days from virus inoculation and microbe contamination including fungi is frequently accompanied during incubation period. We studied whether an immunofocus assay in conjunction with peroxidase-mediated immunohistochemical reaction may replace the standard plaque assay for the virus titration by comparing the two methods. A linear relationship was observed between number of foci and virus dilution. The number of foci in a given dilution of virus appeared a little higher than counted plaques formed in standard plaque assay. Independent titration results obtained from two assay methods for a given dilution of virus demonstrated a strong correlation (r2=0.99). Foci of virus infected cells as revealed by the enzyme reaction could be counted either 4 days post-infection (p.i.) under low magnification (40X) microscopy, or 6 days p.i. by naked eye observation. Larger size of cell cuture plate, virus adsorption at 35 degrees C, and 10% FBS in diluent appeared to be better conditions for the assay. Immunofocus assay will be an effective and dependable titration method for varicella-zoster virus and its live vaccine in place of the standard plaque assay in respect to accuracy, costs, and experimental convenience.
Adsorption ; Fungi ; Herpesvirus 3, Human* ; Microscopy ; Sepharose ; Virion